Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 3
2004 1
2006 3
2007 3
2008 2
2009 2
2010 9
2011 3
2012 2
2014 4
2015 7
2016 6
2017 8
2018 12
2019 12
2020 12
2021 27
2022 15
2023 24
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Results by year

Filters applied: . Clear all
Page 1
Rethinking headache as a global public health case model for reaching the SDG 3 HEALTH by 2030.
Martelletti P, Leonardi M, Ashina M, Burstein R, Cho SJ, Charway-Felli A, Dodick DW, Gil-Gouveia R, Grazzi L, Lampl C, MaassenVanDenBrink A, Minen MT, Mitsikostas DD, Olesen J, Owolabi MO, Reuter U, Ruiz de la Torre E, Sacco S, Schwedt TJ, Serafini G, Surya N, Tassorelli C, Wang SJ, Wang Y, Wijeratne T, Raggi A. Martelletti P, et al. Among authors: reuter u. J Headache Pain. 2023 Oct 27;24(1):140. doi: 10.1186/s10194-023-01666-2. J Headache Pain. 2023. PMID: 37884869 Free PMC article. Review.
European Headache Federation (EHF) critical reappraisal and meta-analysis of oral drugs in migraine prevention - part 3: topiramate.
Raffaelli B, García-Azorín D, Boucherie DM, Amin FM, Deligianni CI, Gil-Gouveia R, Kirsh S, Lampl C, Sacco S, Uluduz D, Versijpt J, MaassenVanDenBrink A, Zeraatkar D, Sanchez-Del-Rio M, Reuter U. Raffaelli B, et al. Among authors: reuter u. J Headache Pain. 2023 Oct 10;24(1):134. doi: 10.1186/s10194-023-01671-5. J Headache Pain. 2023. PMID: 37814223 Free PMC article. Review.
Serum tau protein elevation in migraine: a cross-sectional case-control study.
Overeem LH, Raffaelli B, Fleischmann R, Süße M, Vogelgesang A, Maceski AM, Papadopoulou A, Ruprecht K, Su W, Koch M, Siebert A, Arkuszewski M, Tenenbaum N, Kuhle J, Reuter U. Overeem LH, et al. Among authors: reuter u. J Headache Pain. 2023 Sep 19;24(1):130. doi: 10.1186/s10194-023-01663-5. J Headache Pain. 2023. PMID: 37726712 Free PMC article.
European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention-part 2: flunarizine.
Deligianni CI, Sacco S, Ekizoglu E, Uluduz D, Gil-Gouveia R, MaassenVanDenBrink A, Ornello R, Sanchez-Del-Rio M, Reuter U, Versijpt J, de Vries T, Hussain M, Zeraatkar D, Lampl C. Deligianni CI, et al. Among authors: reuter u. J Headache Pain. 2023 Sep 19;24(1):128. doi: 10.1186/s10194-023-01657-3. J Headache Pain. 2023. PMID: 37723437 Free PMC article. Review.
Impact of headache frequency and preventive medication failure on quality of life, functioning, and costs among individuals with migraine across several European countries: need for effective preventive treatment.
Buse DC, Pozo-Rosich P, Dupont-Benjamin L, Balkaran BL, Lee L, Jauregui A, Gandhi P, Parikh M, Reuter U. Buse DC, et al. Among authors: reuter u. J Headache Pain. 2023 Aug 24;24(1):115. doi: 10.1186/s10194-023-01655-5. J Headache Pain. 2023. PMID: 37612633 Free PMC article.
Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Pozo-Rosich P, Ailani J, Ashina M, Goadsby PJ, Lipton RB, Reuter U, Guo H, Schwefel B, Lu K, Boinpally R, Miceli R, De Abreu Ferreira R, McCusker E, Yu SY, Severt L, Finnegan M, Trugman JM. Pozo-Rosich P, et al. Among authors: reuter u. Lancet. 2023 Sep 2;402(10404):775-785. doi: 10.1016/S0140-6736(23)01049-8. Epub 2023 Jul 26. Lancet. 2023. PMID: 37516125 Clinical Trial.
143 results